This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ibrahim, A. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Ibrahim, A. Articles by Pazdur, R.

Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases

Division of Oncology Drug Products, Center for Drug Evaluation and Research, Rockville, Maryland 20857

ABSTRACT

Purpose: This article summarizes data submitted to the United States Food and Drug Administration for marketing approval of zoledronic acid (Zol; Novartis Pharmaceuticals, East Hanover, NJ), a bisphosphonate drug for treating patients with bone metastases.

Experimental Design: We review the chemistry, toxicology, pharmacology, and clinical study results submitted to support the supplemental New Drug Application for Zol for treatment of patients with bone metastases. Four- and 8-mg Zol doses were selected for Phase III trials based on bone resorption markers and clinical efficacy parameters. Patients with bone metastases were randomized in three Phase III studies (prostate cancer, solid tumors, and multiple myeloma or breast cancer) to receive 4 or 8 mg of Zol or to a control arm. The control was a placebo in the prostate cancer study and the other solid tumor study and was 90 mg of pamidronate (Pam) in the study of breast cancer and multiple myeloma. Studies were amended twice because of renal toxicity, initially to increase Zol infusion time from 5 to 15 min and later to decrease the dose in the Zol 8-mg arm to 4 mg. The efficacy end point was skeletal-related events (SREs), a composite end point consisting of pathologic fracture, radiation therapy to bone, changes in antineoplastic therapy for bone pain (prostate cancer only), surgery to bone, or spinal cord compression. This end point was analyzed either as the proportion of patients with SRE or time to first SRE. The breast cancer and myeloma study used a noninferiority statistical analysis methods to determine efficacy.

Results: In prostate cancer, both the proportions analysis and time-to-SRE analysis showed significantly less bone morbidity on Zol (4 mg) than placebo, but no significant difference between Zol (8 mg) and placebo in either analysis. In the solid tumor study, the time to SRE analysis but not the proportions analysis showed significantly less skeletal morbidity on Zol (4 mg) than placebo, and Zol (8 mg) was significantly better than placebo in both analyses. The breast cancer and myeloma study demonstrated noninferiority of Zol compared with Pam, with Zol retaining at least 49.3% of the Pam treatment effect previously demonstrated in placebo-controlled trials. Zol was approved on February 22, 2002, by the United States Food and Drug Administration for the "treatment of patients with multiple myeloma and documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy." The recommended dose and schedule is 4 mg of Zol infused over 15 min every 3–4 weeks. Increased Zol doses and shorter infusions are not recommended because of potential renal toxicity.

This article has been cited by other articles:

				N. Raje, S.-B. Woo, K. Hande, J. T. Yap, P. G. Richardson, S. Vallet, N. Treister, T. Hideshima, N. Sheehy, S. Chhetri, et al. Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw Clin. Cancer Res., April 15, 2008; 14(8): 2387 - 2395. [Abstract] [Full Text] [PDF]

				T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg Case 9-2008 -- A 65-Year-Old Woman with a Nonhealing Ulcer of the Jaw N. Engl. J. Med., March 20, 2008; 358(12): 1283 - 1291. [Full Text] [PDF]

				C.-H. Cho, Y. Jun Koh, J. Han, H.-K. Sung, H. Jong Lee, T. Morisada, R. A. Schwendener, R. A. Brekken, G. Kang, Y. Oike, et al. Angiogenic Role of LYVE-1-Positive Macrophages in Adipose Tissue Circ. Res., March 2, 2007; 100(4): e47 - e57. [Abstract] [Full Text] [PDF]

				H. Muguruma, S. Yano, S. Kakiuchi, H. Uehara, M. Kawatani, H. Osada, and S. Sone Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity Clin. Cancer Res., December 15, 2005; 11(24): 8822 - 8828. [Abstract] [Full Text] [PDF]

				K. Kawada, H. Minami, K. Okabe, T. Watanabe, K. Inoue, M. Sawamura, Y. Yagi, T. Sasaki, and S. Takashima A Multicenter and Open Label Clinical Trial of Zoledronic Acid 4 mg in Patients with Hypercalcemia of Malignancy Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 28 - 33. [Abstract] [Full Text] [PDF]

				J. Berenson and R. Hirschberg In Response to Diel I, Bergner R. Letter to the Editor of The Oncologist Re: Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid Oncologist, January 1, 2005; 10(1): 84 - 87. [Full Text] [PDF]

				P. G. Richardson, A. Kassarjian, and W. Jing Case 38-2004 - A 40-Year-Old Man with a Large Tumor of the Skull N. Engl. J. Med., December 16, 2004; 351(25): 2637 - 2645. [Full Text] [PDF]

				T. Hiraga, P. J. Williams, A. Ueda, D. Tamura, and T. Yoneda Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model Clin. Cancer Res., July 1, 2004; 10(13): 4559 - 4567. [Abstract] [Full Text] [PDF]

				J. T. Chang, L. Green, J. Beitz, P. Tarassoff, Y.-J. Hei, and D. Maladorno Renal Failure with the Use of Zoledronic Acid N. Engl. J. Med., October 23, 2003; 349(17): 1676 - 1679. [Full Text] [PDF]